- Trials with a EudraCT protocol (11)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
11 result(s) found for: Susceptible individual.
Displaying page 1 of 1.
EudraCT Number: 2008-005045-34 | Sponsor Protocol Number: PPCTP/001 | Start Date*: 2008-12-15 | |||||||||||
Sponsor Name:Profile Pharma Ltd | |||||||||||||
Full Title: A double-blind, vehicle-controlled, multi-centre, clinical study to investigate the efficacy and safety of up to 6 months of therapy with inhaled Promixin in the treatment of patients with non-cyst... | |||||||||||||
Medical condition: non-CF bronchiectasis (CF = cystic fibrosis) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002673-35 | Sponsor Protocol Number: Fos.06/2016 | Start Date*: 2017-03-29 |
Sponsor Name:PRO-IMPLANT Foundation | ||
Full Title: Efficacy and safety of intravenous fosfomycin in prosthetic joint infection (PJI) caused by staphylococci, streptococci, enterococci and gram-negative bacilli, including mixed infections and cultur... | ||
Medical condition: Prosthetic joint infection of knee, hip or shoulder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001396-16 | Sponsor Protocol Number: OP0595-6 | Start Date*: 2023-03-29 | |||||||||||||||||||||||||||||||
Sponsor Name:Meiji Seika Pharma Co., Ltd. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Ur... | |||||||||||||||||||||||||||||||||
Medical condition: Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated ... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) SK (Trial now transitioned) GR (Trial now transitioned) LV (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004677-14 | Sponsor Protocol Number: DIABOLO | Start Date*: 2018-03-09 |
Sponsor Name:Erasmus MC | ||
Full Title: Dose IndividualizAtion of Beta-lactam and fluOroquinoLone AntiBiotics in ICU patients: to TDM or not to TDM and the effects on Outcome (DIABOLO-study) | ||
Medical condition: ICU patients with infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-000472-28 | Sponsor Protocol Number: MK-7264-013 | Start Date*: 2018-06-01 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 2a, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of MK-7264 on Acute Cough in Participants with Induced Viral Upper Respiratory Tract Infe... | |||||||||||||
Medical condition: Acute cough in participants with induced viral upper respiratory tract infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002656-14 | Sponsor Protocol Number: 1733 | Start Date*: 2012-06-11 |
Sponsor Name:Imperial College | ||
Full Title: A randomised, prospective study, assessing changes in cerebral function in treatment naive HIV-1 infected subjects commencing either boosted atazanavir with Truvada or boosted darunavir with maravi... | ||
Medical condition: HIV infection and cognitive function | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003578-34 | Sponsor Protocol Number: 54135419TRD3008 | Start Date*: 2016-08-02 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: An Open-label Long-term Extension Safety Study of Intranasal Esketamine in Treatment resistant Depression | |||||||||||||
Medical condition: Treatment-resistant Major Depression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) ES (Ongoing) PL (Completed) HU (Completed) CZ (Completed) SK (Completed) LT (Completed) AT (Completed) FI (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-005117-31 | Sponsor Protocol Number: W-4282-301 | Start Date*: 2018-10-17 | ||||||||||||||||
Sponsor Name:Wockhardt Bio AG | ||||||||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Multicenter, Comparative Study to Determine the Efficacy and Safety of Cefepime-Tazobactam vs. Meropenem followed by Optional Oral Therapy in the Treatment of... | ||||||||||||||||||
Medical condition: Complicated urinary tract infection or acute pyelonephritis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Temporarily Halted) BG (Temporarily Halted) LV (Completed) LT (Temporarily Halted) PL (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-005721-43 | Sponsor Protocol Number: D4280C00002 | Start Date*: 2012-05-14 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly C... | ||
Medical condition: Complicated Urinary Tract Infections (cUTIs) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Completed) BE (Completed) BG (Completed) DE (Completed) CZ (Completed) SK (Completed) PT (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-005722-21 | Sponsor Protocol Number: D4280C00004 | Start Date*: 2012-06-05 |
Sponsor Name:AstraZeneca AB | ||
Full Title: A Phase III, Randomized, Multicenter, Double-Blind, Double Dummy, Parallel Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime-Avibactam (CAZ-AVI, formerly C... | ||
Medical condition: Complicated Urinary Tract Infections (cUTIs) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GR (Completed) DE (Completed) CZ (Completed) ES (Completed) IT (Completed) BG (Completed) PL (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000344-10 | Sponsor Protocol Number: | Start Date*: 2012-05-24 | |||||||||||||||||||||||||||||||
Sponsor Name:Medical Research Council [...] | |||||||||||||||||||||||||||||||||
Full Title: Adjunctive Rifampicin to Reduce Early mortality from Staphylococcus aureus bacteraemia: a randomised controlled trial | |||||||||||||||||||||||||||||||||
Medical condition: S. aureus bacteraemia | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
